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Abstract
CpG‐related single nucleotide polymorphisms (CGS) have the potential to perturb 
DNA	methylation;	 however,	 their	 effects	 on	Alzheimer	 disease	 (AD)	 risk	 have	 not	
been evaluated systematically. We conducted a genome‐wide association study 
using	a	sliding‐window	approach	to	measure	the	combined	effects	of	CGSes	on	AD	
risk in a discovery sample of 24 European ancestry cohorts (12,181 cases, 12,601 
controls)	from	the	Alzheimer's	Disease	Genetics	Consortium	(ADGC)	and	replication	
sample	of	seven	European	ancestry	cohorts	(7,554	cases,	27,382	controls)	from	the	
International	Genomics	of	Alzheimer's	Project	(IGAP).	The	potential	functional	rele‐
vance	of	significant	associations	was	evaluated	by	analysis	of	methylation	and	expres‐
sion levels in brain tissue of the Religious Orders Study and the Rush Memory and 
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1  | INTRODUC TION
Much	has	been	learned	about	the	genetic	basis	of	Alzheimer	disease	
(AD),	the	most	common	cause	of	dementia	in	the	elderly.	Genome‐wide	
association	studies	(GWAS)	have	identified	common	and	rare	variants	
in	more	than	30	loci	that	contribute	to	AD	risk	(Bellenguez	et	al.,	2017;	
Hollingworth et al., 2011; Jakobsdottir et al., 2016; Jun et al., 2017, 
2016;	Lambert	et	al.,	2013;	Mez	et	al.,	2017;	Naj	et	al.,	2011;	Sims	et	
al.,	2017).	However,	 these	associations	explain	only	a	 fraction	of	 the	
heritability	of	AD,	and	their	functional	consequence	also	remains	un‐
clear	(Lambert	et	al.,	2013;	Ridge,	Mukherjee,	Crane,	&	Kauwe,	2013).	
Thus,	here	we	investigate	AD	risk	from	a	different	perspective.
Epigenetic	phenomena	such	as	DNA	methylation	may	be	involved	
but	have	not	been	studied	extensively	in	AD.	DNA	methylation	is	inti‐
mately	associated	with	genetic	variation	because	of	frequent	attach‐
ment	of	a	methyl	group	directly	to	a	DNA	nucleotide,	particularly	a	
dinucleotide comprising a cytosine and guanine (CpG). CpG‐related 
SNPs	(CGS)	alter	the	sequence	of	the	primary	target	sites	for	DNA	
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Aging	Project	(ROSMAP),	and	in	whole	blood	of	Framingham	Heart	Study	participants	
(FHS). Genome‐wide significant (p < 5 × 10−8) associations were identified with 171 
1.0	kb‐length	windows	spanning	932	kb	in	the	APOE region (top p < 2.2 × 10−308), five 
windows at BIN1 (top p	=	1.3	×	10−13), two windows at MS4A6A (top p = 2.7 × 10−10), 
two windows near MS4A4A (top p = 6.4 × 10−10), and one window at PICALM 
(p	=	6.3	×	10‐9). The total number of CGS‐derived CpG dinucleotides in the window 
near MS4A4A	was	associated	with	AD	risk	(p = 2.67 × 10−10),	brain	DNA	methylation	
(p = 2.15 × 10−10),	and	gene	expression	in	brain	(p	=	0.03)	and	blood	(p	=	2.53	×	10−4). 
Pathway	analysis	of	the	genes	responsive	to	changes	in	the	methylation	quantitative	
trait locus signal at MS4A4A (cg14750746) showed an enrichment of methyltrans‐
ferase	functions.	We	confirm	the	importance	of	CGS	in	AD	and	the	potential	for	cre‐
ating	a	functional	CpG	dosage‐derived	genetic	score	to	predict	AD	risk.
K E Y W O R D S
Alzheimer	disease,	DNA	methylation,	epigenetics,	eQTL,	genetics,	mQTL
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methylation (Lister et al., 2009) and account for a significant frac‐
tion	(~38%–88%)	of	allele‐specific	methylation	(ASM)	regions	in	the	
human genome (Shoemaker, Deng, Wang, & Zhang, 2010). It has been 
demonstrated	that	more	than	80%	of	CGSes	have	a	regulatory	role	in	
DNA	methylation	(Zhi	et	al.,	2013).	Recently,	we	found	that	a	haplo‐
type	of	multiple	CGSes	is	associated	with	DNA	methylation	patterns	
on	a	genome‐wide	scale	(Ma	et	al.,	2016).	DNA	methylation	has	been	
shown to influence risk of age‐related diseases (Hunter et al., 2012; 
De	Jager	et	al.,	2014).	For	example,	a	genome‐wide	DNA	methylation	
study	reported	association	of	AD	pathological	features	with	methyla‐
tion	changes	at	several	loci	(De	Jager	et	al.,	2014).	Also,	levels	of	DNA	
methylation of GSTM1 and GSTM5 have been associated with risk of 
age‐related macular degeneration (Hunter et al., 2012).
In	this	study,	we	evaluated	the	association	of	AD	with	CGSes	ge‐
nome‐wide	and	validated	significant	findings	by	expression	quanti‐
tative	trait	locus	(eQTL)	and	methylation	QTL	(mQTL)	analyses.
2  | RESULTS
2.1 | Sliding Window Association of CGSes with AD
Association	of	AD	with	CGSes	was	tested	genome‐wide	using	sliding	
windows that were 1 kb in length, overlapping by 0.5 kb and con‐
tained at least two CGSes. These analyses, which were performed 
using	 SKAT‐O	 (Lee,	 Wu,	 &	 Lin,	 2012),	 considered	 the	 combined	
effects of all CGSes in a window and weighted rare variants more 
heavily	than	common	variants.	Because	the	SKAT‐O	window‐based	
test does not consider the effect direction of the variants in each 
window, we also tested a model including CGS dosage which was 
calculated as the total number of CpG dinucleotides created by the 
CGSes	 in	 the	 window.	 Genome‐wide	 analysis	 of	 2,288,371	 over‐
lapping windows each containing at least two CGSes showed little 
evidence of inflation (λ	=	1.099,	Figure	S1).	SKAT‐O	and	CGS	dosage	
approaches provided similar results across the genome (Figure S2) 
including five distinct genome‐wide significant loci with windows 
at BIN1	 (SKAT‐O	p = 1.27 × 10−13, CGS dosage p = 4.74 × 10−18), 
MS4A6A	 (SKAT‐O	p = 2.66 × 10−10, CGS dosage p	=	3.40	×	10−10), 
MS4A4A	 (SKAT‐O	p	=	6.36	×	10−10, CGS dosage p = 2.67 × 10−10), 
PICALM	(SKAT‐O	p	=	6.34	×	10−9, CGS dosage p = 1.42 × 10−9), and 
APOE	 (SKAT‐O	 p = 2.99 × 10−46, CGS dosage p = 2.77 × 10−556) 
(Table	1).	Although	the	top	windows	at	BIN1 and PICALM identified 
by	SKAT‐O	do	not	reach	genome‐wide	significance	in	the	CGS	dos‐
age test, the CGS dosage test identified significant associations with 
other windows at these loci. Windows at LRFN2‐UNC5CL and TREM2 
are	genome‐wide	significant	with	only	the	SKAT‐O	test,	whereas	the	
windows at CR1 are genome‐wide significant with only the CGS dos‐
age	test.	All	genome‐wide	significant	windows	identified	by	SKAT‐O	
were replicated (Table 2).
Windows in MS4A4A and MS4A6A showed a strong nega‐
tive	dosage	effect	of	CpG	dinucleotides	on	AD	risk	 (change	 in	 log	
odds	of	AD	=	−0.01	and	−0.02	per	one	unit	dinucleotide	 increase,	
p = 2.67 × 10−10	and	3.4	×	10−10, respectively). This effect was evi‐
dent in 18 out of 24 cohorts (Figure 1). The dosage of CpG dinucleo‐
tides created by the two CGSes in the APOE window has significantly 
positive	association	with	AD	risk	(change	in	log	odds	of	AD	=	0.2	per	
one unit dinucleotide increase, p = 2.77 × 10−556).
TA B L E  1  Top‐ranked	windows	associated	with	AD	by	SKAT‐O	and	CG	dosage	methodologies	in	discovery	stage
Chr Gene Start End
N of 
CGSes
P range of 
CGSes (min, 
max) Window Pa Window Pb Beta (SE)
Common loci identified by two methods
2 BIN1 127,847,001 127,848,000 2 (1.48E−13,	
5.88E−06)
1.27E−13 2.14E−03 −0.02	(0.005)
2 BIN1 127,881,001 127,882,000 2 (2.5E−12,	
3.67E−03)
1.09E−03 4.74E−18 0.18 (0.02)
11 MS4A6A 59,923,001 59,924,000 2 (1.41E−10,	
1.25E−09)
2.66E−10 3.40E−10 −0.01	(0.002)
11 MS4A4A 60,087,501 60,088,500 2 (8.44E−12,	
1.23E−05)
6.36E−10 2.67E−10 −0.02	(0.003)
11 PICALM 85,759,501 85,760,500 2 (3.77E−05,	0.11) 6.34E−09 9.28E−05 0.01 (0.002)
11 PICALM 85,845,001 85,846,000 2 (3.77E−05,	0.11) 5.10E−02 1.42E−09 0.13	(0.02)
19 APOE 45,411,501 45,412,500 2 (<2.23e−308,	
3.56E−28)
2.99E−46 2.77E−556 0.2 (0.004)
Top loci identified by either method
1 CR1 207,737,501 207,738,500 3 (1.49E−10,	0.06) 7.01E−04 8.57E−11 −0.15	(0.02)
6 LRFN2‐UNC5CL 40,825,501 40,826,500 3 (1.38E−06,	0.90) 1.21E−08 8.00E−02 −0.01	(0.005)
6 TREM2 41,128,501 41,129,500 5 (1.34E−06,	0.92) 1.73E−08 6.80E−06 −0.08	(0.002)
aP	values	obtained	by	SKAT‐O	test.	
bP	values	obtained	by	CGSes	dosage	test	and	beta	represent	the	change	in	log	odds	of	AD	per	1‐unit	increase	in	dosage	of	CpG	dinucleotides	com‐
prising the CpG‐related SNPs in the window. 
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In	 order	 to	 show	 the	 unique	 role	 of	CGSes	 in	 these	windows,	
we compared the significance level for the windows under two con‐
ditions, (a) including only CGSes and (b) including only non‐CGSes, 
which are the SNPs that do not disrupt CpG dinucleotide formation. 
As	shown	in	Table	3,	the	p	values	of	all	the	identified	AD‐associated	
windows in Table 1 were attenuated when only non‐CGSes were in‐
cluded in the test. The number of CGSes and non‐CGSes in each 
top	window	differed	by	no	more	than	two	except	for	the	windows	
at MS4A4A and PICALM. There is very modest LD between the top 
CGS	and	non‐CGS	 for	 the	most	of	 the	windows	except	 for	a	win‐
dow at MS4A6A (R2 = 0.98) which is 165 kb from the top window at 
MS4A4A (R2 =	0.37).	The	attenuation	of	 the	 significance	 level	was	
also observed at the individual SNP level for the comparisons of the 
two types of SNPs in each window, noting that the APOE region did 
not contain any non‐CGSes (Table S4).
2.2 | Association of CGSes with DNA 
methylation and gene expression
Windows containing CGSes located in MA4A4A, PICALM and APOE 
were associated (p ≤	0.05)	with	the	degree	of	DNA	methylation	 in	
brains (Table 4); however, only the MS4A4A window was significantly 
associated in brains after correction for the 176 methylation probes 
tested for association (adjusted p = 2.15 × 10−9 at cg14750746). This 
window was also nominally associated with increased methylation in 
blood after correcting for the same 176 methylation probes (nominal T
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F I G U R E  1  Forest	plot	of	dose–response	effect	of	the	number	of	
CpG dinucleotides created by the CGSes in the intergenic window 
close to MS4A4A	on	the	logged	odds	ratio	of	AD.	The	filled	square	
and	horizontal	line	for	each	population	or	the	filled	diamond	for	the	
summary	denote	the	estimated	logged	odds	ratio	and	its	95%	CI	per	
unit increase in the number of CpG dinucleotides in the window
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p	=	3.34	×	10−4 and adjusted p = 0.06). In addition, the number of CpG 
dinucleotides created by the CGSes in the intergenic window be‐
tween MS4A4A and MS4A6E	was	associated	with	increased	expres‐
sion of MS4A4A in both brain (p	=	0.03)	and	blood	(p	=	2.53	×	10−4). 
The MS4A6A	 window	 was	 associated	 with	 DNA	methylation	 (ad‐
justed p = 1.47 × 10−7)	 and	 gene	 expression	 (p = 5.89 × 10−26) in 
blood,	but	rs12226022	was	not	well	imputed	in	the	ROSMAP	data‐
set to test this association in brain.
2.3 | Pathway analysis at the MS4A4A window
Transcriptome	analysis	using	RNAseq	data	from	the	Religious	Order	
Study	and	Rush	Memory	and	Aging	Project	 (ROSMAP)	brain	 sam‐
ples	was	performed	to	 identify	the	set	of	genes	whose	expression	
is influenced by methylation of CpG site cg14750746 that was as‐
sociated with the dosage of MS4A4A CGSes (Table 4). In total, 
15,508 protein‐coding genes remained in the analysis after remov‐
ing	genes	expressed	in	 less	than	10%	subjects.	Although	no	genes	
remained significant after correcting for the number tests (threshold 
p	=	3.2	×	10−6),	there	were	34	nominally	associated	genes	(p < 5×10‐3) 
(Table S5) and pathway analysis showed enrichment in methyltrans‐
ferase activity (Table 5).
3  | DISCUSSION
Our study using a sliding‐window approach confirmed the impor‐
tance	of	CGS	in	AD	and	is	the	first	to	report	dosage	effects	of	CpG	
dinucleotides	created	by	CGSes	on	AD	risk.	 In	particular,	we	 iden‐
tified	 six	windows	with	 a	 significant	effect	of	 the	number	of	CpG	
dinucleotides	on	AD	risk,	including	a	novel	and	robust	dose‐depend‐
ent effect in an intergenic window located between MS4A4A and 
MS4A6E. The number of CpG dinucleotides created by the CGSes 
within	this	window	is	inversely	associated	with	the	risk	of	AD.	The	
potential	functional	importance	of	CGSes	in	AD	is	supported	by	evi‐
dence showing that the significance of almost all of the top windows 
was attenuated when non‐CGSes were included instead of CGSes. 
This observation does not seem to be related to the differences in 
the number of variants or LD between CGSes and non‐CGSes.
The MS4A gene cluster encodes a family of proteins spanning 
the cellular membrane four times which share similar polypeptide 
sequence	and	predicted	topological	structure.	MS4A6A	expression	
in	brain	is	positively	associated	with	AD‐related	neurofibrillary	tan‐
gles	 and	 neuritic	 plaques	 (Karch	 et	 al.,	 2012;	Martiskainen	 et	 al.,	
2015).	AD	risk	alleles	at	these	 loci	were	reported	to	be	associated	
with	higher	expression	in	brain	(Allen	et	al.,	2012;	Karch	et	al.,	2012;	
Martiskainen et al., 2015). The underlying mechanism for the effects 
of MS4A	genes	on	AD	may	be	related	to	their	regulation	of	calcium	
channels	(Walshe	et	al.,	2008),	immune	system	(Zuccolo	et	al.,	2013).	
Our findings of an association of the CpG dinucleotide dosage in 
this	region	with	AD	risk	suggest	a	potential	novel	AD‐related	mech‐
anism involving MS4A	genes.	Further	experiments	examining	DNA	
methylation in the MS4A	 region	are	necessary	 to	clarify	 the	exact	
mechanism.
All	of	the	loci	identified	in	our	study	using	a	sliding‐window	ap‐
proach	were	previously	reported	to	be	associated	with	AD	through	
DNA	methylation	analyses,	 indicating	 an	overlap	between	genetic	
and	 epigenetic	mechanisms.	 For	 example,	 brain	DNA	methylation	
levels of CpG sites located in the top‐ranked loci have been asso‐
ciated	with	clinical	and	pathological	diagnoses	of	AD	in	a	sample	of	
740	ROSMAP	participants,	many	of	whom	are	included	in	the	ADGC	
GWAS	dataset	(De	Jager	et	al.,	2014).	The	mQTL	CpG	sites	identified	
in our study are correlated with the previously reported (De Jager 
et	 al.,	 2014)	AD‐associated	CpG	 sites	 in	 both	 brain	 and	 blood	 (all	
p < 0.05) (Table S6), but it is unclear why the pairs of methylation 
probes in MS4A region and APOE are inversely correlated in brain 
and blood.
All	of	the	genes	identified	by	our	analyses	have	been	implicated	
in inflammation and the immune system. BIN1 knock‐out mice 
were shown to have higher incidence of inflammation during aging 
(Chang et al., 2007). BIN1 was also reported to be related to inflam‐
mation and immunity by its participation in the phagocytic pathway 
(Gold	et	al.,	2004)	and	regulation	of	critical	enzymes	against	patho‐
gens (Muller, DuHadaway, Donover, Sutanto‐Ward, & Prendergast, 
TA B L E  3   Comparisons of the top windows containing CGSes versus non‐CGSes
Chr Start End Gene
P of window N of variants
LD between CGS and non‐
CGS (R2)
CGS Non‐CGS CGS Non‐CGS
Top 
CGS and 
non‐CGS
Any pairs 
(min, max)
2 127,847,001 127,848,000 BIN1 1.27E−13 3.30E−05 2 2 0.01 (2.38E−05,	
0.01)
11 59,923,001 59,924,000 MS4A6A 2.66E−10 0.786 2 4 0.98 (8.73E−03,	
0.98)
11 60,087,501 60,088,500 MS4A4A 6.36E−10 0.029 2 9 0.37 (5.99E−04,	1)
11 85,759,501 85,760,500 PICALM 6.34E−09 0.035 2 6 0.15 (1.33E−03,	
0.24)
19 45,411,501 45,412,500 APOE 2.99E−46 NA 2 0 NA NA
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2005). Genes in the MS4A family have been shown to activate T 
cells and trigger production of inflammatory cytokines (Yan et al., 
2013).	 Expression	 of	 PICALM was reduced in subjects who un‐
derwent gastric bypass surgery to reverse their pro‐inflammatory 
state of obesity (Ghanim et al., 2012), and PICALM	overexpression	
in	 vitro	 was	 found	 to	 reduce	 the	 endosomal	 localization	 of	 the	
mannose‐6‐phosphate receptor (M6PR) which binds to the herpes 
virus (Brunetti, Dingwell, Wale, Graham, & Johnson, 1998). It is still 
controversial whether APOE‐ε4 causes anti‐ or pro‐inflammatory 
effects, but it is generally accepted that APOE is related to inflam‐
mation (Dorey, Chang, Liu, Yang, & Zhang, 2014). Our collective 
findings	suggest	that	DNA	methylation	may	be	a	molecular	mech‐
anism	underlying	aberrant	inflammatory	responses	related	to	AD.
Our findings also suggest that the sliding‐window approach 
focused on CGSes is useful for identifying loci whose influence on 
disease risk may involve clinically relevant epigenetic mechanisms. 
In	 the	 large	 GWAS	 conducted	 by	 the	 International	 Genomics	 of	
Alzheimer's	Project	(Lambert	et	al.,	2013),	approximately	44%	of	the	
top	AD‐associated	SNPs	are	CGSes.	However,	not	all	of	these	CGSes	
were	significantly	associated	with	AD	in	our	analysis	(e.g.,	CGSes	in	
CR1, CD2AP, and CLU; Table S1). Interestingly, none of these three 
loci were reported to have significant brain methylation changes re‐
lated	 to	AD	pathology	 (De	Jager	et	al.,	2014),	 indicating	 that	 their	
effects	on	AD	may	not	involve	DNA	methylation.
Our	study	has	several	limitations.	All	the	identified	top	windows	
for	AD	were	previously	reported	loci	associated	with	AD	(Guerreiro	
et	 al.,	 2013;	 Jonsson	 et	 al.,	 2013;	 Lambert	 et	 al.,	 2013;	Naj	 et	 al.,	
2011).	This	was	expected	because	the	samples	of	our	and	previously	
published	GWAS	are	highly	overlapping.	However,	our	study	ascribes	
potential function to some of these results, especially those occur‐
ring in noncoding regions. In order to identify the relative impor‐
tance of the CGSes in the top windows compared to non‐CGSes, we 
performed	conditional	analysis	adjusting	for	the	top	GWAS	SNP.	For	
all	windows,	the	association	signal	for	both	the	GWAS	SNP	and	CpG	
dosage was attenuated when both were included in the model. In 
particular, for the intergenic window between MS4A4A and MS4A6E, 
the p‐values	for	both	CpG	dosage	and	the	GWAS	variant	had	similar	
reduction	in	significance	(Table	S7).	The	squared	correlation	(r2) be‐
tween	the	GWAS	variant	and	the	CGS	with	the	largest	influence	on	
the dosage effect in MS4A4A window is 0.56. Thus, it is not possi‐
ble	 to	 conclude	 from	 the	 conditional	 analysis	whether	 the	GWAS	
variant, the window CpG dosage, or another variant in the region 
that is correlated with both of these markers, is responsible for the 
association. We did not remove CGSes in high LD, which may inflate 
the number of significant findings. However, some of these associ‐
ations may be independent because multiple adjacent methylated 
CpG sites can serve as the platform for chromatin binding proteins 
that	lead	to	changes	in	chromatin	state	(Bartke	et	al.,	2010).	Another	
concern	is	that	despite	experimental	evidence	suggesting	an	optimal	
window	size	of	1kb,	it	is	unknown	whether	other	window	sizes	may	
increase	power.	Also,	our	 selection	of	 the	default	weights	of	vari‐
ants has bias toward rare variants. Finally, we observed that the CGS 
most	significantly	associated	with	AD	risk	also	has	significant	mQTL	
and	eQTL	effects	that	survive	regional	multiple	test	correction	but	
do not achieve genome‐wide significance.
In	conclusion,	we	confirmed	the	 importance	of	CGS	 in	AD	and	
the potential for creating a functional genetic score based on CpG 
dosage to predict disease risk. However, it is unknown whether 
these	CGS	signals	act	as	causative	mechanisms	in	AD	progression.	
Further replication and mechanistic studies are necessary to validate 
these	findings.	Future	genome‐wide	mQTL	and	eQTL	analyses	may	
extend	our	findings.
4  | E XPERIMENTAL PROCEDURES
4.1 | Genome‐wide association analysis of CGSes 
with AD
4.1.1 | CGS annotation
CGSes were annotated as described previously (Ma et al., 2016). In 
brief,	CGS	information	was	retrieved	by	Galaxy	(Goecks,	Nekrutenko,	
Taylor,	&	Galaxy,	2010)	from	UCSC	human	genome	browser	based	
on	SNP141	and	human	hg19	sequence	data.
TA B L E  4  Association	between	CGSes	and	methylation	and	gene	expression
Gene Position Name
Methylation of CpG site Gene expression
Brain Blood Brain Blood
Beta (SE)a P1a P2a Pb Beta (SE)a P1a P2a Beta (SE)a pa Pb Beta (SE)a pa
BIN1 127,800,646 cg00436254 −1.87E−04	(2.28E−03) 0.93 1.00 2.08E−03 −5.48E−03	(6.40E−04) 1.97E−17 5.56E−15 2.40 (2.27) 0.29 0.41 −8.40E−03	(4.15E−03) 0.04
MS4A6A 59,824,541 cg01917716 NA NA NA NA −2.91E−03	(4.72E−04) 8.13E−10 1.47E−07 NA NA NA −0.04	(3.55E−03) 5.89E−26
MS4A4A 60,101,475 cg14750746 5.60E−03	(8.11E−04) 1.22E−11 2.15E−09 0.03 −2.49E−03	(6.93E−04) 3.34E−04 0.06 0.14 (0.07) 0.03 0.07 0.09 (0.02) 2.53E−04
PICALM 85,566,560 cg15822411 −3.42E−03	(1.77E−03) 0.05 1.00 1.00 −6.97E−04	(4.10E−04) 0.09 1.00 3.14E−03	(0.41) 0.99 0.76 7.68E−03	(5.11E−03) 0.13
APOE 45,395,297 cg02613937 −9.96E−04	(4.19E−04) 0.02 1.00 0.42 −4.25E−03	(2.90E−03) 0.14 1.00 −2.93	(6.19) 0.64 0.60 6.94E−03	(6.13E−03) 0.26
aStatistics obtained from CGSes dosage tests. P1 represents uncorrected p‐values, and P2 represents Bonferroni corrected p‐values calculated by  
multiplying the number of methylation probes included in the test which are within 1Mb distance to the window. 
bStatistics	obtained	from	SKAT‐O	tests.	
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4.1.2 | Discovery stage subjects
The discovery stage included 12,181 unrelated cases and 12,601 
controls from 22 cohorts with European ancestry participating in 
the	 Alzheimer's	 Disease	 Genetic	 Consortium	 (ADGC)	 (Table	 S2).	
Characteristics	of	the	ADC7	cohort	are	provided	in	the	Appendix	S1,	
and details of other study cohorts were previously described (Jun 
et	al.,	2016;	Lambert	et	al.,	2013).	Studies	of	the	individual	cohorts	
were approved by the appropriate Institutional Review Boards, and 
written informed consent for all subjects was provided on behalf of 
TA B L E  4  Association	between	CGSes	and	methylation	and	gene	expression
Gene Position Name
Methylation of CpG site Gene expression
Brain Blood Brain Blood
Beta (SE)a P1a P2a Pb Beta (SE)a P1a P2a Beta (SE)a pa Pb Beta (SE)a pa
BIN1 127,800,646 cg00436254 −1.87E−04	(2.28E−03) 0.93 1.00 2.08E−03 −5.48E−03	(6.40E−04) 1.97E−17 5.56E−15 2.40 (2.27) 0.29 0.41 −8.40E−03	(4.15E−03) 0.04
MS4A6A 59,824,541 cg01917716 NA NA NA NA −2.91E−03	(4.72E−04) 8.13E−10 1.47E−07 NA NA NA −0.04	(3.55E−03) 5.89E−26
MS4A4A 60,101,475 cg14750746 5.60E−03	(8.11E−04) 1.22E−11 2.15E−09 0.03 −2.49E−03	(6.93E−04) 3.34E−04 0.06 0.14 (0.07) 0.03 0.07 0.09 (0.02) 2.53E−04
PICALM 85,566,560 cg15822411 −3.42E−03	(1.77E−03) 0.05 1.00 1.00 −6.97E−04	(4.10E−04) 0.09 1.00 3.14E−03	(0.41) 0.99 0.76 7.68E−03	(5.11E−03) 0.13
APOE 45,395,297 cg02613937 −9.96E−04	(4.19E−04) 0.02 1.00 0.42 −4.25E−03	(2.90E−03) 0.14 1.00 −2.93	(6.19) 0.64 0.60 6.94E−03	(6.13E−03) 0.26
aStatistics obtained from CGSes dosage tests. P1 represents uncorrected p‐values, and P2 represents Bonferroni corrected p‐values calculated by  
multiplying the number of methylation probes included in the test which are within 1Mb distance to the window. 
bStatistics	obtained	from	SKAT‐O	tests.	
TA B L E  5  Enrichment	of	methyltransferase	activities	in	the	regulatory	network	of	MS4A	cluster‐associated	CpG	site	(cg14750746)	in	
brain using Gene Ontology (GO) terms
GO term ID GO term description P FDR
GO:0050313 sulfur	dioxygenase	activity 8.31E−04 0.03
GO:0008276 protein methyltransferase activity 1.19E−03 0.03
GO:0008170 N‐methyltransferase activity 1.23E−03 0.03
GO:0070905 serine binding 1.66E−03 0.03
GO:0003713 transcription coactivator activity 1.69E−03 0.03
GO:0004843 ubiquitin‐specific	protease	activity 2.44E−03 0.03
GO:0042799 histone	methyltransferase	activity	(H4‐K20	specific) 2.49E−03 0.03
GO:0019783 ubiquitin‐like	protein‐specific	protease	activity 2.95E−03 0.03
GO:0036459 ubiquitinyl	hydrolase	activity 3.01E−03 0.03
GO:0008234 cysteine‐type peptidase activity 8.70E−03 0.06
GO:0008139 nuclear	localization	sequence	binding 9.11E−03 0.06
GO:0008168 methyltransferase activity 9.91E−03 0.06
GO:0016741 transferase activity, transferring one‐carbon groups 0.01 0.06
GO:0003756 protein disulfide isomerase activity 0.02 0.08
GO:0016864 intramolecular	oxidoreductase	activity,	transposing	S‐S	bonds 0.02 0.08
GO:0005096 GTPase activator activity 0.02 0.08
GO:0016702 oxidoreductase	activity,	acting	on	single	donors	with	incorporation	of	
molecular	oxygen,	incorporation	of	two	atoms	of	oxygen
0.02 0.08
GO:0016701 oxidoreductase	activity,	acting	on	single	donors	with	incorporation	of	
molecular	oxygen
0.02 0.08
GO:0030695 GTPase regulator activity 0.02 0.08
GO:0005048 signal	sequence	binding 0.02 0.08
GO:0060589 nucleoside‐triphosphatase regulator activity 0.02 0.09
GO:0018024 histone‐lysine N‐methyltransferase activity 0.03 0.09
GO:0016278 lysine N‐methyltransferase activity 0.03 0.10
GO:0016279 protein‐lysine N‐methyltransferase activity 0.03 0.10
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themselves or for substantially cognitively impaired subjects, by a 
caregiver,	legal	guardian,	or	other	proxy.
4.2 | Statistical analysis
Details	of	SNP	genotyping	and	quality	control	are	described	else‐
where	(Jun	et	al.,	2016;	Lambert	et	al.,	2013).	SNP	genotype	impu‐
tation was performed using IMPUTE2 with reference haplotypes 
from the March 2012 release of 1,000 Genomes. Principal compo‐
nent (PC) analysis was conducted using the smartpca program in 
EIGENSOFT (Patterson, Price, & Reich, 2006; Price et al., 2006) to 
evaluate	population	substructure	within	each	dataset.	Association	
of	AD	risk	with	CGSes	was	tested	using	a	sliding‐window	approach	
(Tang, Feng, Sha, & Zhang, 2009). Windows spanning 1kb were 
constructed	based	on	evidence	suggesting	that	sequence	variants	
within 1 kb can affect the methylation status of a gene (Lienert et 
al., 2011). Consecutive windows with a 500 bp overlap were tested 
to	optimize	power	for	detection	of	associations	and	ensure	a	suf‐
ficient	number	of	SNPs	 in	each	window.	Thus,	 for	example,	each	
unique	2000	bp	region	contains	three	overlapping	windows.	CGSes	
with	imputation	quality	(r2)	≤0.4	or	genotype	data	available	for	less	
than half of the cohorts were removed. Windows with fewer than 
two	CGSes	were	 omitted	 from	 the	 analysis.	 After	 these	 filtering	
steps,	2,288,371	windows	remained	for	association	analyses.
The	 association	 of	 AD	 with	 the	 combined	 effects	 of	 multiple	
CGSes	in	each	window	on	the	risk	of	AD	was	evaluated	by	logistic	re‐
gression	using	the	optimal	sequence	kernel	association	test	(SKAT‐O)	
(Lee	et	al.,	2012)	using	R	package	seqMeta	(https	://cran.r‐proje	ct.org/
web/packa	ges/seqMe	ta/index.html)	 as	 implemented	 in	 Universal	
Genome	 Analyst	 (UGA)	 software	 (https	://github.com/rmkoe	stere	r/
uga). The fast P value calculation “integration” method was used as 
a screening tool. Windows with p	≤	5	×	10‐4 or no reported p value 
were	 re‐analyzed	 using	 the	 “saddlepoint”	method	 (Duchesne	&	 de	
Micheaux,	2010).	We	used	the	default	weights	of	the	seqMeta	pack‐
age to up weight the contributions from rare variants with the aim to 
identify potential novel loci. The same methodology was applied to 
the	analysis	of	non‐CGSes.	SKAT‐O	is	not	sensitive	to	effect	direction	
of the individual variants included in the test and thus does not pro‐
duce	effect	estimates.	Thus,	we	also	conducted	the	dose–response	
effect	of	the	multiple	CGSes	in	the	window	on	AD	risk	using	logistic	
regression. The allele that creates a CpG dinucleotide was considered 
as the effect allele and the allele that disrupts the CpG dinucleotide 
as the reference allele. The sum of the imputed dosages for multiple 
CGSes	in	each	window	was	calculated	and	used	as	the	exposure	vari‐
able	for	the	logistic	regression	model	with	AD	status	as	the	outcome.	
The summary statistics for regression coefficients and robust stan‐
dard	errors	 from	each	cohort	were	meta‐analyzed	using	an	 inverse	
variance‐weighted,	 fixed‐effects	 approach	 implemented	 in	METAL	
(Willer,	Li,	&	Abecasis,	2010).	Both	SKAT‐O	and	dosage	analyses	were	
adjusted	 for	age,	 sex,	 and	PCs.	Windows	surviving	Bonferroni‐cor‐
rected genome‐wide significance level (p	≤	5	×	10−8) from both meth‐
odologies were considered. The genome‐wide summary statistics 
from the two methodologies are provided in Table S8.
4.2.1 | Replication testing
Cohort‐specific	 GWAS	 summary	 statistics	 were	 obtained	 from	 a	
prior	AD	GWAS	conducted	by	the	IGAP	consortium,	which	includes	
7,554	 unrelated	 cases	 and	 27,382	 controls	 from	 the	 Cohorts	 for	
Heart	 and	 Aging	 Research	 in	 Genomic	 Epidemiology	 (CHARGE)	
consortium,	the	European	Alzheimer's	Disease	Initiative	(EADI),	and	
the	Genetic	and	Environmental	Risk	in	Alzheimer's	Disease	(GERAD)	
consortium	 (Lambert	 et	 al.,	 2013).	 The	 protocols	 and	 participant	
consent forms were approved by each institution. The combined ef‐
fects	 of	multiple	CGSes	 in	 each	window	on	AD	were	 determined	
using	the	GATES	method,	implemented	in	the	GATES	R	package	(Li,	
Gui,	Kwan,	&	Sham,	2011).	This	method	extends	the	Simes	test	to	
combine the p‐values of the SNPs within a region into an overall 
regional p value.
4.3 | mQTL Analysis
Brain	 mQTL	 was	 obtained	 for	 740	 subjects	 (mean	 age	 at	
death	=	88	years,	63.6%	female)	from	the	Religious	Order	Study	and	
Rush	Memory	and	Aging	Project	(ROSMAP),	and	blood	mQTL	data	
obtained	from	2,405	participants	(mean	age	=	66	years,	54%	female)	
of	the	Framingham	Heart	Study	(FHS)	Offspring	cohort	at	examina‐
tion	8	were	downloaded	from	dbGAP	(Table	S3).	DNA	methylation	
profiles for both studies were measured by the Illumina Infinium 
HumanMethylation450	BeadChip.	Analyses	of	FHS	data	were	con‐
ducted	in	two	stages.	A	linear	mixed	model	was	used	to	derive	the	
residuals	of	the	DNA	methylation	of	the	probe	adjusted	for	the	im‐
puted	cell	types	(CD8T,	CD4T,	NK,	B‐cell,	monocyte),	row	and	col‐
umn	as	fixed‐effects,	chip	ID	as	a	random	effect	at	first.	Then,	each	
residual was regressed on the CGSes dosage in models including age 
and	sex	as	fixed‐effects	and	kinship	matrix	as	random	effect	to	ac‐
count	for	familial	correlation.	Analyses	of	ROSMAP	data	were	con‐
ducted with the linear model by adjusting the methylation batch, age 
at	death,	sex,	post‐mortem	interval,	and	study	group	(ROS	or	MAP),	
which was test to be the most appropriate model for the data as 
reported by De Jager et al. (2014). p‐values were adjusted using a 
Bonferroni correction for the total number of probes tested within 
each window.
4.4 | eQTL analysis
Brain	RNAseq	data	were	obtained	for	580	ROSMAP	subjects	(mean	
age	at	death	=	89	years,	63.3%	female),	and	whole	blood	array‐based	
expression	data	for	5,252	FHS	Offspring	cohort	(examination	8)	and	
Generation	 3	 (examination	 2)	 participants	 (mean	 age	 =	 55	 years,	
54%	female)	were	obtained	from	dbGAP	 (Supplementary	Table	3).	
Normalized	gene	expression	level	was	regressed	on	the	sum	of	dos‐
ages of CpG dinucleotides in each window with covariates for age, 
sex,	and	the	first	three	PCs	of	ancestry	using	a	linear	mixed	model	
for analyses of FHS data and a general linear model for analyses of 
ROSMAP	data.	p‐Values	were	corrected	for	the	seven	tests	 (i.e.,	7	
genes) performed.
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4.5 | Pathway analysis
Using	 the	 ROSMAP	 brain	methylation	 and	 RNAseq	 data,	 we	 per‐
formed	a	genome‐wide	expression‐methylation	scan	using	a	general	
linear	model	with	the	methylation	of	CpG	site	cg14750476	as	the	ex‐
posure	variable	and	the	normalized	gene	expression	levels	of	all	the	
protein‐coding genes as outcomes (n = 15,508), including the same 
covariates	as	in	the	mQTL	and	eQTL	analyses.	Genes	with	p < 0.005 
were included in the pathway enrichment analysis implemented 
in	 the	software	of	STRINGdb	 (Szklarczyk	et	al.,	2015),	which	con‐
ducted a hypergeometric test, using the false discovery rate (FDR) 
to	correct	for	multiple	tests	(Benjamini,	1995),	to	query	the	enrich‐
ment of the input gene sets against the background gene list in Gene 
Ontology database classified as “molecular function”.
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